Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Ba869911bbc7e7aedd8ab913e3039c99a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Ba869911bbc7e7aedd8ab913e3039c99a NCIT_P378 "NCI" @default.
- Ba869911bbc7e7aedd8ab913e3039c99a type Axiom @default.
- Ba869911bbc7e7aedd8ab913e3039c99a annotatedProperty IAO_0000115 @default.
- Ba869911bbc7e7aedd8ab913e3039c99a annotatedSource NCIT_C156933 @default.
- Ba869911bbc7e7aedd8ab913e3039c99a annotatedTarget "A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) derived from a human anti-CD30 monoclonal antibody, with potential immunostimulating and antineoplastic activities. Upon administration, the human anti-CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. Compared to CAR-T cells that use murine scFv-based CARs, CAR-T cells containing CARs with human scFv regions reduces the immunogenicity of the CAR-T cells and may improve their longevity." @default.